Enrique Lara-Pezzi

List of Publications by Year
in descending order

90 papers	6,274 citations	76326 40 h-index	69250 77 g-index
96 all docs	96 docs citations	96 times ranked	9119 citing authors

#	Article	IF	Citations
1	Understanding Cardiac Physiological Hypertrophy in a LncRNA Way. Journal of Cardiovascular Translational Research, 2022, 15, 3.	2.4	1
2	Best Paper of the Year 2021. Journal of Cardiovascular Translational Research, 2022, 15, 1-2.	2.4	2
3	Functional Impact and Regulation of Alternative Splicing in Mouse Heart Development and Disease. Journal of Cardiovascular Translational Research, 2022, 15, 1239-1255.	2.4	6
4	Higher order dynamic mode decomposition: From fluid dynamics to heart disease analysis. Computers in Biology and Medicine, 2022, 144, 105384.	7.0	10
5	Non-coding region variants upstream of MEF2C cause severe developmental disorder through three distinct loss-of-function mechanisms. American Journal of Human Genetics, 2021, 108, 1083-1094.	6.2	42
6	Glycated Hemoglobin and SubclinicalÂAtherosclerosis in People Without Diabetes. Journal of the American College of Cardiology, 2021, 77, 2777-2791.	2.8	49
7	Early Preventive Treatment With Enalapril Improves Cardiac Function and Delays Mortality in Mice With Arrhythmogenic Right Ventricular Cardiomyopathy Type 5. Circulation: Heart Failure, 2021, 14, e007616.	3.9	3
8	The SRSF4â€“GAS5-Glucocorticoid Receptor Axis Regulates Ventricular Hypertrophy. Circulation Research, 2021, 129, 669-683.	4.5	11
9	Association of Genetic Variants With Outcomes in Patients With Nonischemic Dilated Cardiomyopathy. Journal of the American College of Cardiology, 2021, 78, 1682-1699.	2.8	55
10	Assessment of myocardial viscoelasticity with Brillouin spectroscopy in myocardial infarction and aortic stenosis models. Scientific Reports, 2021, 11, 21369.	3.3	3
11	dSreg: a Bayesian model to integrate changes in splicing and RNA-binding protein activity. Bioinformatics, 2020, 36, 2134-2141.	4.1	1
12	Machine Learning Improves Cardiovascular Risk Definition for Young,ÂAsymptomatic Individuals. Journal of the American College of Cardiology, 2020, 76, 1674-1685.	2.8	44
13	Association Between Body Size Phenotypes and Subclinical Atherosclerosis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3734-3744.	3.6	18
14	Clinical characteristics and determinants of the phenotype in TMEM43 arrhythmogenic right ventricular cardiomyopathy type 5. Heart Rhythm, 2020, 17, 945-954.	0.7	28
15	Short-Term Progression of Multiterritorial Subclinical Atherosclerosis. Journal of the American College of Cardiology, 2020, 75, 1617-1627.	2.8	55
16	Complement C5 Protein as a Marker of Subclinical Atherosclerosis. Journal of the American College of Cardiology, 2020, 75, 1926-1941.	2.8	32
17	WWP2 regulates pathological cardiac fibrosis by modulating SMAD2 signaling. Nature Communications, 2019, 10, 3616.	12.8	44
18	Severe Cardiac Dysfunction and Death Caused by Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Are Improved by Inhibition of Glycogen Synthase Kinase-3Î². Circulation, 2019, 140, 1188-1204.	1.6	62

#	Article	IF	Citations
19	Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 156-163.	3.0	33
20	Loss of SRSF3 in Cardiomyocytes Leads to Decapping of Contraction-Related mRNAs and Severe Systolic Dysfunction. Circulation Research, 2019, 125, 170-183.	4.5	41
21	Genetic Variants Associated With Cancer Therapyâ€"Induced Cardiomyopathy. Circulation, 2019, 140, 31-41.	1.6	195
22	Association of Sleep Duration and Quality With Subclinical Atherosclerosis. Journal of the American College of Cardiology, 2019, 73, 134-144.	2.8	145
23	CnAÎ²1 shifts cardiac metabolism. Aging, 2019, 11, 839-840.	3.1	2
24	Activation of Serine One-Carbon Metabolism by Calcineurin AÎ²1 Reduces Myocardial Hypertrophy and Improves Ventricular Function. Journal of the American College of Cardiology, 2018, 71, 654-667.	2.8	45
25	Hâ€•<i>ras</i> deletion protects against angiotensin IIâ€"induced arterial hypertension and cardiac remodeling through protein kinase Gâ€•Î² pathway activation. FASEB Journal, 2018, 32, 920-934.	0.5	9
26	MouBeAT: A New and Open Toolbox for Guided Analysis of Behavioral Tests in Mice. Frontiers in Behavioral Neuroscience, 2018, 12, 201.	2.0	28
27	Genetic Etiology for Alcohol-Induced Cardiac Toxicity. Journal of the American College of Cardiology, 2018, 71, 2293-2302.	2.8	182
28	Usefulness of Genetic Testing in Hypertrophic Cardiomyopathy: an Analysis Using Real-World Data. Journal of Cardiovascular Translational Research, 2017, 10, 35-46.	2.4	10
29	Bloodless reperfusion with the oxygen carrier HBOC-201 in acute myocardial infarction: a novel platform for cardioprotective probes delivery. Basic Research in Cardiology, 2017, 112, 17.	5.9	30
30	Lung ultrasound as a translational approach for non-invasive assessment of heart failure with reduced or preserved ejection fraction in mice. Cardiovascular Research, 2017, 113, 1113-1123.	3.8	19
31	Lafora Disease Is an Inherited Metabolic Cardiomyopathy. Journal of the American College of Cardiology, 2017, 69, 3007-3009.	2.8	6
32	Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. European Heart Journal, 2017, 38, 1895-1904.	2.2	258
33	Genetically Confirmed Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome. Journal of the American College of Cardiology, 2017, 70, 1732-1740.	2.8	111
34	Current State of Basic and Translational Cardiovascular Research in Spain. Circulation Research, 2017, 121, 1036-1039.	4.5	4
35	Systolic Dysfunction in Infarcted Mice Does Not Necessarily Lead to Heart Failure: Need to Refine Preclinical Models. Journal of Cardiovascular Translational Research, 2017, 10, 499-501.	2.4	2
36	Animal models of arrhythmogenic right ventricular cardiomyopathy: what have we learned and where do we go? Insight for therapeutics. Basic Research in Cardiology, 2017, 112, 50.	5.9	20

#	Article	IF	Citations
37	Neurogenesis: Regulation by Alternative Splicing and Related Posttranscriptional Processes. Neuroscientist, 2017, 23, 466-477.	3.5	22
38	Alternative Splicing of NOX4 in the Failing Human Heart. Frontiers in Physiology, 2017, 8, 935.	2.8	32
39	ATtRACTâ€”a database of RNA-binding proteins and associated motifs. Database: the Journal of Biological Databases and Curation, 2016, 2016, baw035.	3.0	215
40	Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. Journal of the American College of Cardiology, 2016, 68, 2440-2451.	2.8	340
41	The Calcineurin Variant CnAÎ²1 Controls Mouse Embryonic Stem Cell Differentiation by Directing mTORC2 Membrane Localization and Activation. Cell Chemical Biology, 2016, 23, 1372-1382.	5.2	30
42	Intravenous delivery of adeno-associated virus 9-encoded IGF-1Ea propeptide improves post-infarct cardiac remodelling. Npj Regenerative Medicine, 2016, 1, 16001.	5.2	12
43	Matrix cross-linking lysyl oxidases are induced in response to myocardial infarction and promote cardiac dysfunction. Cardiovascular Research, 2016, 109, 67-78.	3.8	103
44	Genetic basis of familial dilated cardiomyopathy patients undergoing heart transplantation. Journal of Heart and Lung Transplantation, 2016, 35, 625-635.	0.6	60
45	Technologies to Study Genetics and Molecular Pathways. , 2016, , 251-269.		0
46	Guidelines for Translational Research in Heart Failure. Journal of Cardiovascular Translational Research, 2015, 8, 3-22.	2.4	28
47	Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. European Heart Journal, 2015, 36, 2585-2594.	2.2	789
48	<i>ZBTB17</i> (<i>MIZ1</i>) Is Important for the Cardiac Stress Response and a Novel Candidate Gene for Cardiomyopathy and Heart Failure. Circulation: Cardiovascular Genetics, 2015, 8, 643-652.	5.1	12
49	Workshop on cardiovascular extracellular matrix in health and disease in Baeza, Spain. Fibrogenesis and Tissue Repair, 2015, 8, 2.	3.4	0
50	Review and Updates in Regenerative and Personalized Medicine, Preclinical Animal Models, and Clinical Care in Cardiovascular Medicine. Journal of Cardiovascular Translational Research, 2015, 8, 466-474.	2.4	4
51	FineSplice, enhanced splice junction detection and quantification: a novel pipeline based on the assessment of diverse RNA-Seq alignment solutions. Nucleic Acids Research, 2014, 42, e71-e71.	14.5	30
52	Induction of the calcineurin variant CnAÎ²1 after myocardial infarction reduces post-infarction ventricular remodelling by promoting infarct vascularization. Cardiovascular Research, 2014, 102, 396-406.	3.8	24
53	Advances in Induced Pluripotent Stem Cells, Genomics, Biomarkers, and Antiplatelet Therapy Highlights of the Year in JCTR 2013. Journal of Cardiovascular Translational Research, 2014, 7, 518-525.	2.4	3
54	Genetics in dilated cardiomyopathy. Biomarkers in Medicine, 2013, 7, 517-533.	1.4	42

#	Article	IF	Citations
55	The Alternative Heart: Impact of Alternative Splicing in Heart Disease. Journal of Cardiovascular Translational Research, 2013, 6, 945-955.	2.4	76
56	Understanding cardiovascular disease: a journey through the genome (and what we found there). DMM Disease Models and Mechanisms, 2012, 5, 434-443.	2.4	40
57	The Vascular Stem Cell Niche. Journal of Cardiovascular Translational Research, 2012, 5, 618-630.	2.4	62
58	Follistatin-Like 3 Mediates Paracrine Fibroblast Activation by Cardiomyocytes. Journal of Cardiovascular Translational Research, 2012, 5, 814-826.	2.4	35
59	The molecular and pathophysiological implications of hepatitis B X antigen in chronic hepatitis B virus infection. Reviews in Medical Virology, 2011, 21, 315-329.	8.3	40
60	Cardiac Myocyte-specific Ablation of Follistatin-like 3 Attenuates Stress-induced Myocardial Hypertrophy. Journal of Biological Chemistry, 2011, 286, 9840-9848.	3.4	37
61	Calcineurin Splicing Variant Calcineurin Aβ1 Improves Cardiac Function After Myocardial Infarction Without Inducing Hypertrophy. Circulation, 2011, 123, 2838-2847.	1.6	54
62	Revealing New Mouse Epicardial Cell Markers through Transcriptomics. PLoS ONE, 2010, 5, e11429.	2.5	61
63	Analysis of Cardiac Myocyte Biology in Transgenic Mice: A Protocol for Preparation of Neonatal Mouse Cardiac Myocyte Cultures. Methods in Molecular Biology, 2010, 633, 113-124.	0.9	18
64	Genetic Enhancement of Cardiac Regeneration. , 2010, , 981-997.		0
65	Cyclooxygenase-2 Mediates Dialysate-Induced Alterations of the Peritoneal Membrane. Journal of the American Society of Nephrology: JASN, 2009, 20, 582-592.	6.1	65
66	Activin A and Follistatin-Like 3 Determine the Susceptibility of Heart to Ischemic Injury. Circulation, 2009, 120, 1606-1615.	1.6	83
67	A Gene Expression Profile of the Myocardial Response to Clenbuterol. Journal of Cardiovascular Translational Research, 2009, 2, 191-197.	2.4	13
68	Expression of Extracellular Matrix Genes During Myocardial Recovery From Heart Failure After Left Ventricular Assist Device Support. Journal of Heart and Lung Transplantation, 2009, 28, 117-122.	0.6	49
69	The hepatitis B virus X protein induces paracrine activation of human hepatic stellate cells. Hepatology, 2008, 47, 1872-1883.	7.3	95
70	Expression of Follistatin-Related Genes Is Altered in Heart Failure. Endocrinology, 2008, 149, 5822-5827.	2.8	82
71	Expression and Regulation of the Metalloproteinase ADAM-8 during Human Neutrophil Pathophysiological Activation and Its Catalytic Activity on L-Selectin Shedding. Journal of Immunology, 2007, 178, 8053-8063.	0.8	103
72	A naturally occurring calcineurin variant inhibits FoxO activity and enhances skeletal muscle regeneration. Journal of Cell Biology, 2007, 179, 1205-1218.	5.2	62

#	Article	IF	Citations
73	Enhancing Repair of the Mammalian Heart. Circulation Research, 2007, 100, 1732-1740.	4.5	101
74	Hepatitis B Virus Promotes Angiopoietin-2 Expression in Liver Tissue. American Journal of Pathology, 2006, 169, 1215-1222.	3.8	70
75	Evidence of a Transcriptional Co-activator Function of Cohesin STAG/SA/Scc3. Journal of Biological Chemistry, 2004, 279, 6553-6559.	3.4	49
76	Hepatitis C virus core protein regulates p300/CBP co-activation function. Possible role in the regulation of NF-AT1 transcriptional activity. Virology, 2004, 328, 120-130.	2.4	15
77	Immunohistochemical characterization of fibroblast subpopulations in normal peritoneal tissue and in peritoneal dialysis-induced fibrosis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 444, 247-256.	2.8	106
78	N-Acetyl-cysteine modulates inducible nitric oxide synthase gene expression in human hepatocytes. Journal of Hepatology, 2004, 40, 632-637.	3.7	62
79	Peritoneal Dialysis and Epithelial-to-Mesenchymal Transition of Mesothelial Cells. New England Journal of Medicine, 2003, 348, 403-413.	27.0	694
80	Peritoneal Dialysis and Epithelial-to-Mesenchymal Transition. New England Journal of Medicine, 2003, 348, 2037-2039.	27.0	5
81	The Hepatitis B Virus X Protein Binds to and Activates the NH2-Terminal trans-Activation Domain of Nuclear Factor of Activated T Cells-1. Virology, 2002, 299, 288-300.	2.4	21
82	The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression. Journal of Clinical Investigation, 2002, 110, 1831-1838.	8.2	89
83	The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression. Journal of Clinical Investigation, 2002, 110, 1831-1838.	8.2	155
84	Effect of the hepatitis B virus HBx protein on integrin-mediated adhesion to and migration on extracellular matrix. Journal of Hepatology, 2001, 34, 409-415.	3.7	71
85	The hepatitis B virus X protein (HBx) induces a migratory phenotype in a CD44-dependent manner: Possible role of HBx in invasion and metastasis. Hepatology, 2001, 33, 1270-1281.	7.3	78
86	Hepatitis B virus X protein transactivates inducible nitric oxide synthase gene promoter through the proximal nuclear factor [kappa]B[ndash]binding site: Evidence that cytoplasmic location of X protein is essential for gene transactivation. Hepatology, 2001, 34, 1218-1224.	7.3	41
87	The hepatitis B virus HBx protein induces adherens junction disruption in a src-dependent manner. Oncogene, 2001, 20, 3323-3331.	5.9	82
88	The Hepatitis B Virus X Protein Induces HIV-1 Replication and Transcription in Synergy with T-cell Activation Signals. Journal of Biological Chemistry, 2001, 276, 35435-35443.	3.4	95
89	The hepatitis B virus X protein activates nuclear factor of activated T cells (NF-AT) by a cyclosporin A-sensitive pathway. EMBO Journal, 1998, 17, 7066-7077.	7.8	91
90	The hepatitis B virus X protein up-regulates tumor necrosis factor Î± gene expression in hepatocytes. Hepatology, 1998, 28, 1013-1021.	7.3	114